We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies. The drug is meant for the treatment of adults and pediatric patients with HIV-1 infection (weighing at least 40 kg).
In such patients – adult or pediatric – the recommended dosage is 1,200 mg, comprising two 600 mg tablets once daily for the treatment of HIV-1 in treatment-naïve patients or patients whose virus remains suppressed after treatment with an initial regimen of 400 mg of Isentress twice-daily. Presently, Isentress is approved in a 400 mg twice daily formulation for the treatment of HIV-1 infection in adults.
We remind investors that the once-daily formulation of Isentress (600 mg tablets) received positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) earlier this month. A final decision on approval is expected in the second half of 2017.
Shares of Merck have outperformed the Zacks classified Large Cap Pharma industry in the last one year. The stock has gained 15.2% during the period, while the broader industry witnessed an increase of 1.8%.
Coming back to the latest news, the approval was supported by data from a phase III pivotal study (ONCEMRK) evaluating the efficacy and safety of Isentress in treatment-naive HIV-1 infected patients.
After 48 weeks of treatment, 89% of the patients in the Isentress HD arm (given as 2 x 600 mg once-daily) achieved viral suppression of HIV-1 RNA (<40 copies/mL) compared to 88% in the Isentress 400 mg twice-daily arm, each in combination therapy with Gilead Sciences Inc.’s (GILD - Free Report) Truvada.
The company expects Isentress HD to be made available in pharmacies approximately in the next four weeks. We note that Isentress faces competitive pressure and is being impacted by slowing growth of the integrase class. Sales of the drug declined 10% in the first quarter of 2017 and 8% in 2016.
Merck currently carries a Zacks Rank #2 (Buy). Stocks worth considering in the health care sector include VIVUS, Inc. and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) . VIVUS sports a Zacks Rank #1 (Strong Buy) while Regeneron carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all the four trailing quarters with an average beat of 233.69%.
Regeneron’s earnings per share estimates increased from $10.17 to $10.52 for 2017 and from $10.90 to $12.10 for 2018 over the last 30 days. The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 0.45%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck's HIV Drug Isentress Gets FDA Approval for Higher Dose
Merck & Co., Inc. (MRK - Free Report) recently announced that the FDA has approved Isentress HD, a new 1,200 mg once daily dose of its marketed drug Isentress (raltegravir), in combination with other anti-retroviral therapies. The drug is meant for the treatment of adults and pediatric patients with HIV-1 infection (weighing at least 40 kg).
In such patients – adult or pediatric – the recommended dosage is 1,200 mg, comprising two 600 mg tablets once daily for the treatment of HIV-1 in treatment-naïve patients or patients whose virus remains suppressed after treatment with an initial regimen of 400 mg of Isentress twice-daily. Presently, Isentress is approved in a 400 mg twice daily formulation for the treatment of HIV-1 infection in adults.
We remind investors that the once-daily formulation of Isentress (600 mg tablets) received positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) earlier this month. A final decision on approval is expected in the second half of 2017.
Shares of Merck have outperformed the Zacks classified Large Cap Pharma industry in the last one year. The stock has gained 15.2% during the period, while the broader industry witnessed an increase of 1.8%.
Coming back to the latest news, the approval was supported by data from a phase III pivotal study (ONCEMRK) evaluating the efficacy and safety of Isentress in treatment-naive HIV-1 infected patients.
After 48 weeks of treatment, 89% of the patients in the Isentress HD arm (given as 2 x 600 mg once-daily) achieved viral suppression of HIV-1 RNA (<40 copies/mL) compared to 88% in the Isentress 400 mg twice-daily arm, each in combination therapy with Gilead Sciences Inc.’s (GILD - Free Report) Truvada.
The company expects Isentress HD to be made available in pharmacies approximately in the next four weeks. We note that Isentress faces competitive pressure and is being impacted by slowing growth of the integrase class. Sales of the drug declined 10% in the first quarter of 2017 and 8% in 2016.
Merck & Company, Inc. Price
Merck & Company, Inc. Price | Merck & Company, Inc. Quote
Zacks Rank & Key Picks
Merck currently carries a Zacks Rank #2 (Buy). Stocks worth considering in the health care sector include VIVUS, Inc. and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) . VIVUS sports a Zacks Rank #1 (Strong Buy) while Regeneron carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’s loss per share estimates narrowed from 50 cents to 39 cents for 2017 over the last 30 days. The company posted positive earnings surprises in all the four trailing quarters with an average beat of 233.69%.
Regeneron’s earnings per share estimates increased from $10.17 to $10.52 for 2017 and from $10.90 to $12.10 for 2018 over the last 30 days. The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 0.45%.
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>